Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sevelda

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
Anticancer Research|May 16, 2000
First report of lymphatic mapping with isosulfan blue dye and sentinel node biopsy in cervical cancerM Medl, C Peters-Engl, P Schütz, et al.
Anticancer Research|January 19, 1999
TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancerC Peters-Engl, P Buxbaum, E Ogris, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1992
[Breech presentation in primiparous patients: indications for primary Cesarean section?]P Sevelda, M Stiglbauer, N Vavra, et al.
Gynakologische Rundschau|January 1, 1990
[CA-12 tumor marker values in serum following radioimmuno-scintigraphy]M Barrada, N Pateisky, C Schatten, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1986
[Labor induction with 3 mg of prostaglandin E2 vaginal tablets. A renaissance of programmed labor? Results of a prospective randomized study]P Husslein, C Egarter, P Sevelda, et al.
Geburtshilfe Und Frauenheilkunde|June 1, 1993
[Breech presentation in nulliparous women--vaginal delivery or indications for primary section?]P Sevelda, M Stiglbauer, N Vavra, et al.
Gynecologic Oncology|November 1, 1991
Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels?P Sevelda, A Rosen, U Denison, et al.
Gynecologic Oncology|June 1, 1995
Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeksA Obermair, N Vavra, C Kurz, et al.
Gynakologische Rundschau|January 1, 1989
[Cesarean section versus vaginal delivery of breech presentation in primiparous patients]M Stiglbauer, P Sevelda, N Vavra, et al.
Gynakologische Rundschau|January 1, 1990
[Goserelin--a new form of hormone therapy in ovarian cancer]N Vavra, M Barrada, R Fitz, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
Anticancer Research|May 16, 2000
First report of lymphatic mapping with isosulfan blue dye and sentinel node biopsy in cervical cancerM Medl, C Peters-Engl, P Schütz, et al.
Anticancer Research|January 19, 1999
TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancerC Peters-Engl, P Buxbaum, E Ogris, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1992
[Breech presentation in primiparous patients: indications for primary Cesarean section?]P Sevelda, M Stiglbauer, N Vavra, et al.
Gynakologische Rundschau|January 1, 1990
[CA-12 tumor marker values in serum following radioimmuno-scintigraphy]M Barrada, N Pateisky, C Schatten, et al.
Geburtshilfe Und Frauenheilkunde|February 1, 1986
[Labor induction with 3 mg of prostaglandin E2 vaginal tablets. A renaissance of programmed labor? Results of a prospective randomized study]P Husslein, C Egarter, P Sevelda, et al.
Geburtshilfe Und Frauenheilkunde|June 1, 1993
[Breech presentation in nulliparous women--vaginal delivery or indications for primary section?]P Sevelda, M Stiglbauer, N Vavra, et al.
Gynecologic Oncology|November 1, 1991
Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels?P Sevelda, A Rosen, U Denison, et al.
Gynecologic Oncology|June 1, 1995
Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeksA Obermair, N Vavra, C Kurz, et al.
Gynakologische Rundschau|January 1, 1989
[Cesarean section versus vaginal delivery of breech presentation in primiparous patients]M Stiglbauer, P Sevelda, N Vavra, et al.
Gynakologische Rundschau|January 1, 1990
[Goserelin--a new form of hormone therapy in ovarian cancer]N Vavra, M Barrada, R Fitz, et al.
Pageof 15